<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>94(4)</volume><submitter>Akingbola TS</submitter><funding>Doris Duke Charitable Foundation</funding><journal>American journal of hematology</journal><pagination>E112-E115</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6440541</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.</pubmed_title><pmcid>PMC6440541</pmcid><funding_grant_id>2013140</funding_grant_id><pubmed_authors>Sonubi O</pubmed_authors><pubmed_authors>Hsu LL</pubmed_authors><pubmed_authors>Gordeuk VR</pubmed_authors><pubmed_authors>Molokie R</pubmed_authors><pubmed_authors>Cooper RS</pubmed_authors><pubmed_authors>Tayo BO</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Akingbola TS</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>Saraf SL</pubmed_authors><pubmed_authors>Ezekekwu CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.</name><description/><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Apr</publication><modification>2025-04-04T09:44:28.097Z</modification><creation>2025-04-04T09:44:28.097Z</creation></dates><accession>S-EPMC6440541</accession><cross_references><pubmed>30663794</pubmed><doi>10.1002/ajh.25412</doi></cross_references></HashMap>